Date | Research Firm | Action | Current | PT |
---|---|---|---|---|
4/01/21 | SVB Leerink | Maintains | Outperform | 66.0 |
3/02/21 | Stifel | Initiates Coverage On | Buy | 64.0 |
2/18/21 | Needham | Initiates Coverage On | Buy | 75.0 |
12/09/20 | Chardan Capital | Maintains | Buy | 56.0 |
12/08/20 | Chardan Capital | Maintains | Buy | 46.0 |
12/08/20 | Oppenheimer | Downgrades | Perform | |
10/16/20 | Chardan Capital | Maintains | Buy | 35.0 |
7/02/20 | JP Morgan | Initiates Coverage On | Overweight | 38.0 |
6/25/20 | B of A Securities | Reinstates | Buy | 34.0 |
12/09/19 | Oppenheimer | Maintains | Outperform | 42.0 |
Rocket Pharmaceuticals analyst ratings
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.